Authentification abonné
lvrea
Accueil Tous les numéros Volume 25 / Numéro 1 (Janvier 2016) Réanimation, 25 1 (2016) 123-131 Références
Accès gratuit
Numéro
Réanimation
Volume 25, Numéro 1, Janvier 2016
Respiratoire
Page(s) 123 - 131
Section Mise Au Point / Update
DOI https://doi.org/10.1007/s13546-015-1157-4
Publié en ligne 6 janvier 2016
  • Lepoutre A, Antona D, Fonteneau L, et al (2013) Seroprevalence of vaccine-preventable diseases and five other infectious diseases in France. Results of two national surveys 2008-2010. Bull Epidemiol Hebd 41-42:526–34 [Google Scholar]
  • Duncan AJ, Dummer JS, Paradis IL, et al (1991) Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 10:638–44 [PubMed] [Google Scholar]
  • Ljungman P, Aschan J, Lewensohn-Fuchs I, et al (1998) Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients. Transplantation 66:1330–4 [CrossRef] [PubMed] [Google Scholar]
  • Osarogiagbon RU, Defor TE, Weisdorf MA, et al (2000) CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biol Blood Marrow Transplant 6:280–8 [CrossRef] [PubMed] [Google Scholar]
  • San Juan R, Aguado JM, Lumbreras C, et al (2008) Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation. Clin Infect Dis 47:875–82 [CrossRef] [PubMed] [Google Scholar]
  • Ljungman P, de la Camara R, Cordonnier C, et al (2008) Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 42:227–40 [CrossRef] [PubMed] [Google Scholar]
  • Kotton CN, Kumar D, Caliendo AM, et al (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89:779–95 [CrossRef] [PubMed] [Google Scholar]
  • Gandhi MK, Khanna R (2004) Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 4:725–38 [CrossRef] [PubMed] [Google Scholar]
  • Crumpacker CS (1996) Ganciclovir. N Engl J Med 335:721–9 [CrossRef] [PubMed] [Google Scholar]
  • Biron KK (2006) Antiviral drugs for cytomegalovirus diseases. Antiviral Res 71:154–63 [CrossRef] [PubMed] [Google Scholar]
  • Wutzler P, Thust R (2001) Genetic risks of antiviral nucleoside analogues--a survey. Antiviral Res 49:55–74 [CrossRef] [PubMed] [Google Scholar]
  • Piketty C, Bardin C, Gilquin J, et al (2000) Monitoring plasma levels of ganciclovir in AIDS patients receiving oral ganciclovir as maintenance therapy for CMV retinitis. Clin Microbiol Infect 6:117–20 [CrossRef] [PubMed] [Google Scholar]
  • Wiltshire H, Paya CV, Pescovitz MD, et al (2005) Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 79:1477–83 [CrossRef] [PubMed] [Google Scholar]
  • Zhang D, Lapeyraque AL, Popon M, et al (2003) Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Pediatr Nephrol 18:943–8 [CrossRef] [PubMed] [Google Scholar]
  • Vethamuthu J, Feber J, Chretien A, et al (2007) Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children. Pediatr Transplant 11:301–5 [CrossRef] [PubMed] [Google Scholar]
  • Luck S, Lovering A, Griffiths P, Sharland M (2011) Ganciclovir treatment in children: evidence of subtherapeutic levels. Int J Antimicrob Agents 37:445–8 [CrossRef] [PubMed] [Google Scholar]
  • Pescovitz MD, Ettenger RB, Strife CF, et al (2010) Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Transpl Infect Dis 12:195–203 [CrossRef] [PubMed] [Google Scholar]
  • Hantz S, Garnier-Geoffroy F, Mazeron MC, et al (2010) Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 65:2628–40 [CrossRef] [PubMed] [Google Scholar]
  • Boivin G, Goyette N, Rollag H, et al (2009) Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 14:697–704 [PubMed] [Google Scholar]
  • Li F, Kenyon KW, Kirby KA, et al (2007) Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients. Clin Infect Dis 45:439–47 [CrossRef] [PubMed] [Google Scholar]
  • Limaye AP, Corey L, Koelle DM, et al (2000) Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645–9 [CrossRef] [PubMed] [Google Scholar]
  • Boutolleau D, Deback C, Bressollette-Bodin C, et al (2009) Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection. Antiviral Res 81:174–9 [CrossRef] [PubMed] [Google Scholar]
  • Lurain NS, Chou S (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23:689–712 [CrossRef] [PubMed] [Google Scholar]
  • Hamprecht K, Eckle T, Prix L, et al (2003) Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 187:139–43 [CrossRef] [PubMed] [Google Scholar]
  • Miller GG, Boivin G, Dummer JS, et al (2006) Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient. Clin Infect Dis 42:e26–9 [CrossRef] [PubMed] [Google Scholar]
  • Moss HB, Chavala S, Say E, Miller MB (2012) Ganciclovir-resistant cytomegalovirus (CMV) retinitis in a patient with wild-type CMV in her plasma. J Clin Microbiol 50:1796–9 [CrossRef] [PubMed] [Google Scholar]
  • Blackman SC, Lurain NS, Witte DP, et al (2004) Emergence and compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency. J Pediatr Hematol Oncol 26:601–5. [CrossRef] [PubMed] [Google Scholar]
  • Frange P, Boutolleau D, Leruez-Ville M, et al (2013) Temporal and spatial compartmentalization of drug-resistant cytomegalovirus (CMV) in a child with CMV meningoencephalitis: implications for sampling in molecular diagnosis. J Clin Microbiol 51:4266–9 [CrossRef] [PubMed] [Google Scholar]
  • Jung D, Dorr A (1999) Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 39:800–4 [CrossRef] [PubMed] [Google Scholar]
  • Perrottet N, Decosterd LA, Meylan P, et al (2009) Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin Pharmacokinet 48:399–418 [CrossRef] [PubMed] [Google Scholar]
  • Asberg A, Humar A, Rollag H, et al (2007) Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7:2106–13 [CrossRef] [PubMed] [Google Scholar]
  • Vaudry W, Ettenger R, Jara P, et al (2009) Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients. Am J Transplant 9:636–43 [CrossRef] [PubMed] [Google Scholar]
  • Eksborg S (2003) The pharmacokinetics of antiviral therapy in paediatric patients. Herpes 10:66–71 [PubMed] [Google Scholar]
  • Wagstaff AJ, Bryson HM (1994) Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 48:199–226 [CrossRef] [PubMed] [Google Scholar]
  • Jacobson MA (1997) Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 337:105–14 [CrossRef] [PubMed] [Google Scholar]
  • Safrin null, Cherrington null, Jaffe null (1997) Clinical uses of cidofovir. Rev Med Virol 7:145–56 [CrossRef] [PubMed] [Google Scholar]
  • Jacobson MA, Wulfsohn M, Feinberg JE, et al (1994) Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. AIDS 8:451–9 [CrossRef] [PubMed] [Google Scholar]
  • Boutolleau D, Canestri A, Burrel S, et al (2012) Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection. J Clin Virol 54:194–6 [CrossRef] [PubMed] [Google Scholar]
  • Dropulic LK, Cohen JI (2010) Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin Pharmacol Ther 88:610–9 [CrossRef] [PubMed] [Google Scholar]
  • Drew WL, Miner RC, Marousek GI, Chou S (2006) Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol 37:124–7 [CrossRef] [PubMed] [Google Scholar]
  • Marty FM, Ljungman P, Papanicolaou GA, et al (2011) Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis 11:284–92 [CrossRef] [PubMed] [Google Scholar]
  • Marty FM, Boeckh M (2011) Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed? Curr Opin Virol 1:555–62 [CrossRef] [PubMed] [Google Scholar]
  • Alain S, Revest M, Veyer D, et al (2013) Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc 45:1603–7 [CrossRef] [PubMed] [Google Scholar]
  • Eid AJ, Razonable RR (2010) New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 70:965–81 [CrossRef] [PubMed] [Google Scholar]
  • Avery RK, Mossad SB, Poggio E, et al (2010) Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation 90:419–26 [CrossRef] [PubMed] [Google Scholar]
  • Ciszek M, Mucha K, Foroncewicz B, et al (2014) Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient--a case report. Ann Transplant 19:60–3 [CrossRef] [PubMed] [Google Scholar]
  • Verkaik NJ, Hoek R a. S, van Bergeijk H, et al (2013) Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature. Transpl Infect Dis 15:E243–9 [CrossRef] [PubMed] [Google Scholar]
  • Sellar RS, Ward KN, Thomson KJ, Peggs KS (2012) Evidence for clinical activity of artesunate in multidrug-resistant herpes simplex infection following HSCT. Bone Marrow Transplant 47:1482–3 [CrossRef] [PubMed] [Google Scholar]
  • Wolf DG, Shimoni A, Resnick IB, et al (2011) Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 90:183–6 [CrossRef] [PubMed] [Google Scholar]
  • Shapira MY, Resnick IB, Chou S, et al (2008) Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis 46:1455–7 [CrossRef] [PubMed] [Google Scholar]
  • Lau PK, Woods ML, Ratanjee SK, John GT (2011) Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection. Clin Infect Dis 52:279 [Google Scholar]
  • Germi R, Mariette C, Alain S, et al (2014) Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res 101:57–61. [CrossRef] [PubMed] [Google Scholar]
  • Lischka P, Hewlett G, Wunberg T, et al (2010) In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother 54:1290–7 [Google Scholar]
  • Marschall M, Stamminger T, Urban A, et al (2012) In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother 56:1135–7 [Google Scholar]
  • Kaul DR, Stoelben S, Cober E, et al (2011) First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 11:1079–84 [CrossRef] [PubMed] [Google Scholar]
  • Chemaly RF, Ullmann AJ, Stoelben S, et al (2014) Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 370:1781–9 [CrossRef] [PubMed] [Google Scholar]
  • Stoelben S, Arns W, Renders L, et al (2014) Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transpl Int 27:77–86 [CrossRef] [PubMed] [Google Scholar]
  • Chou S (2015) Rapid In Vitro Evolution of Human Cytomegalovirus UL56 Mutations That Confer Letermovir Resistance. Antimicrob Agents Chemother 59:6588–93 [CrossRef] [PubMed] [Google Scholar]
  • Marty FM, Winston DJ, Rowley SD, et al (2013) CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med 369:1227–36 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.